---
title: "VK2735 in Chronic weight management: Effects on other drugs"
description: "Formulary evidence on VK2735 in Chronic weight management: Effects on other drugs. Topics: Class context: tirzepatide (Zepbound) with insulin or an insulin secretagogue; Class context: tirzepatide (Zepbound) with oral medications and oral hormonal contraceptives; Class context: tirzepatide (Zepbound) effects on CYP enzymes, transporters, and oral contraceptive exposure. 3 evidence topics quoted from 1 source."
canonical: "https://www.evicenter.com/drugs/vk2735--chronic-weight-management/product-information-and-disease-description/effects-on-other-drugs"
published: "2026-11-15T21:45:47-05:00"
modified: "2026-11-15T21:45:47-05:00"
---

# VK2735 in Chronic weight management: Effects on other drugs

<a id="heading-2.1.2.9.2"></a>

## 2.1.2.9.2 Effects of VK2735 on Other Drugs

<a id="topic-2.1.2.9.2-1"></a>

### Clinical drug interaction studies with either formulation

No evidence found.

<a id="topic-2.1.2.9.2-2"></a>

### Effect of VK2735 on gastric emptying and absorption of oral medications

No evidence found.

<a id="topic-2.1.2.9.2-3"></a>

### Class context: tirzepatide (Zepbound) with insulin or an insulin secretagogue

> “ZEPBOUND lowers blood glucose. When initiating ZEPBOUND, consider reducing the dose of concomitantly administered insulin or insulin secretagogues (e.g., sulfonylureas) to reduce the risk of hypoglycemia”

Source: [Eli Lilly Zepbound prescribing information (2026)](https://uspl.lilly.com/zepbound/zepbound.html)

<a id="topic-2.1.2.9.2-4"></a>

### Class context: tirzepatide (Zepbound) with oral medications and oral hormonal contraceptives

> “ZEPBOUND delays gastric emptying and thereby has the potential to impact the absorption of concomitantly administered oral medications. Caution should be exercised when oral medications are concomitantly administered with ZEPBOUND.”
> “Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation with ZEPBOUND and for 4 weeks after each dose escalation.”

Source: [Eli Lilly Zepbound prescribing information (2026)](https://uspl.lilly.com/zepbound/zepbound.html)

<a id="topic-2.1.2.9.2-5"></a>

### Class context: tirzepatide (Zepbound) effects on CYP enzymes, transporters, and oral contraceptive exposure

> “In vitro studies have shown low potential for tirzepatide to inhibit or induce CYP enzymes, and to inhibit drug transporters.”
> “Following administration of a combined oral contraceptive (0.035 mg ethinyl estradiol and 0.25 mg norgestimate) in the presence of a single dose of tirzepatide 5 mg, mean C max of ethinyl estradiol, norgestimate, and norelgestromin was reduced by 59%, 66%, and 55%, while mean AUC was reduced by 20%, 21%, and 23%, respectively.”

Source: [Eli Lilly Zepbound prescribing information (2026)](https://uspl.lilly.com/zepbound/zepbound.html)

## Related pages
- [VK2735: Chronic weight management](https://www.evicenter.com/drugs/vk2735--chronic-weight-management) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management.md)
- [VK2735 in Chronic weight management: Terms and abbreviations](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/terms-and-abbreviations.md)
- [VK2735: Chronic weight management](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/executive-summary) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/executive-summary.md)
- [VK2735 in Chronic weight management: Product information and disease description](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/product-information-and-disease-description.md)
- [VK2735 in Chronic weight management: Clinical evidence](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/clinical-evidence.md)
- [VK2735 in Chronic weight management: Economic information and modeling report](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/economics) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/economics.md)
- [VK2735 in Chronic weight management: References](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/references) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/references.md)
